Brief Summary
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcomacancer arising from bones and/or soft tissue viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectalrelating to the colon or rectum in the large bowel/intestine cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs who have previously received chemotherapy.
Intervention / Treatment
- Biological: Amivantamab
- Biological: Cetuximab
- Biological: Bevacizumab
- Drug: 5-fluorouracil
- Drug: Leucovorin calcium/Levoleucovorin
- Drug: Irinotecan
Inclusion Criteria:
- Have histologically or cytologically confirmed adenocarcinomacancer arising from mucus-producing glands in organs of the colonthe longest portion of the large bowel that absorbs water and salts from ingested food or rectumthe last section of the large intestine/bowel that holds waste until it is ready to be removed from the body. Participants must have recurrent, unresectable or metastatic disease
- Be diagnosed to have KRAS, NRAS, and BRAF wild-type (WT) tumor as determined by local testing
- Must agree to the submission of fresh or archival tumor tissuea group of cells that work together to perform a function post-progression from the most recent therapy, if clinically feasible
- Have measurable disease according to RECIST v1.1
- Have an eastern cooperative oncologythe study, diagnosis and treatment of cancer group (ECOG) performance status (PS) of 0 or 1
- Participant must have received 1 line of systemic therapy (fluoropyrimidine-based and oxaliplatin-based) for metastatic colorectal cancer (mCRC), with documented radiographic disease progression on or after this line of therapy